Next-Generation Quinone-Containing Conjugates for Selective Cancer Treatment

A paradigm-shifting approach to antibody drug conjugates (ADCs) featuring microdose regimens, tumor-specific stimuli-responsive payloads, and gene editing tools to revolutionize cancer therapy.

The original patent disclosed quinone-containing conjugates for detection and treatment of proliferative disorders. However, these conjugates had limitations in terms of efficacy, systemic toxicity, and lack of tumor specificity. The new inventive concept addresses these limitations by introducing next-generation ADCs with enhanced targeting capabilities, improved efficacy, and reduced toxicity.

The new inventive concept comprises a system for selectively targeting and destroying tumor cells using conjugates of formula (I) with cytotoxic molecules linked to antibodies via cleavable linkers. The conjugates are administered in microdose regimens to enhance efficacy while minimizing systemic toxicity. Additionally, the payload is selectively released in response to specific tumor microenvironment stimuli, ensuring targeted delivery. The composition of matter includes conjugates with quinone-containing payloads that are selectively activated by tumor-specific enzymes. Furthermore, the conjugates can be designed with gene editing tools that selectively target tumor-specific gene mutations, allowing for precise cancer therapy. The system also enables detection and treatment of proliferative disorders using conjugates with fluorescent probes that selectively bind to tumor-specific biomarkers.

The new claims introduce novel concepts such as microdose regimens, tumor-specific stimuli-responsive payloads, and gene editing tools, which are not present in the original patent. These innovations provide a significant improvement over the existing ADC technology, making the new inventive concept non-obvious and novel.

Alternative embodiments of the inventive concept may include varying the linker chemistry, modifying the payload structure, or using different antibody formats. Variations of the gene editing tool could include CRISPR-Cas9 or other RNA-guided nucleases. The system could also be adapted for use in other diseases beyond cancer, such as autoimmune disorders or infectious diseases.

The next-generation quinone-containing conjugates have significant commercial potential in the cancer therapy market, which is projected to reach $150 billion by 2025. The technology could be licensed to pharmaceutical companies or developed in-house, with potential partnerships with biotech companies, research institutions, and hospitals.